Genmab Profit Margin

The latest profit margin for GMAB is 9.74% as of June 2026. That compares with 41.42% in the prior-year period — down 76.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Genmab's historical trend and sector peers before judging valuation or financial health.

Over the past year, GMAB's profit margin moved from 41.42% to 9.74% — a 76.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genmab's valuation or profitability profile.

Against Healthcare companies, GMAB currently prints 9.74% for profit margin, while the sector average sits near 13.89%. That is roughly 29.9% below the sector mean. Large gaps often invite a closer look at Genmab's growth, margins, and balance sheet.

Profit Margin shows how effectively Genmab converts resources into returns. At 9.74%, GMAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 41.42% in the prior-year period — down 76.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GMAB's profit margin (9.74%), review year-over-year change from 41.42%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.